As of 2026-01-09, the Intrinsic Value of Viking Therapeutics Inc (VKTX) is -10.50 USD. This VKTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 31.65 USD, the upside of Viking Therapeutics Inc is -133.18%.
Based on its market price of 31.65 USD and our intrinsic valuation, Viking Therapeutics Inc (VKTX) is overvalued by 133.18%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -10.50 - -10.50 | -10.50 | -133.18% |
| P/E | (31.25) - (41.58) | (38.85) | -222.8% |
| DDM - Stable | (11.74) - (43.59) | (27.66) | -187.4% |
| DDM - Multi | (0.09) - (0.25) | (0.13) | -100.4% |
| Market Cap (mil) | 3,577.72 |
| Beta | 0.98 |
| Outstanding shares (mil) | 113.04 |
| Enterprise Value (mil) | 3,477.34 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.43% |
| Cost of Debt | 5.00% |
| WACC | 8.05% |